• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The 2021 European Society of Cardiology Cardiovascular Disease Prevention Guidelines: adding albuminuria to the SCORE scale increases the prevalence of very high/high cardiovascular risk among patients with chronic kidney disease.

作者信息

Cebrian Ana, Escobar Carlos, Aranda Unai, Palacios Beatriz, Capel Margarita, Sicras Antoni, Sicras Aram, Hormigo Antonio, Manito Nicolás, Botana Manuel, Alcázar Roberto

机构信息

Primary care center Cartagena Casco, Cartagena, Murcia, Spain.

University hospital La Paz, Madrid, Spain.

出版信息

Clin Kidney J. 2022 Feb 10;15(6):1204-1208. doi: 10.1093/ckj/sfac019. eCollection 2022 Jun.

DOI:10.1093/ckj/sfac019
PMID:35664262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9155243/
Abstract
摘要

相似文献

1
The 2021 European Society of Cardiology Cardiovascular Disease Prevention Guidelines: adding albuminuria to the SCORE scale increases the prevalence of very high/high cardiovascular risk among patients with chronic kidney disease.《2021年欧洲心脏病学会心血管疾病预防指南》：将蛋白尿纳入SCORE量表会增加慢性肾病患者中极高/高心血管风险的患病率。
Clin Kidney J. 2022 Feb 10;15(6):1204-1208. doi: 10.1093/ckj/sfac019. eCollection 2022 Jun.
2
Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of Cardiology.在 24 个欧洲国家的冠心病患者中慢性肾脏病的流行情况及其决定因素：来自欧洲心脏病学会 EUROASPIRE IV 调查的见解。
Eur J Prev Cardiol. 2017 Jul;24(11):1168-1180. doi: 10.1177/2047487317708891. Epub 2017 May 15.
3
Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines.美国心脏协会/美国心脏病学会/多学会、美国预防服务工作组、美国退伍军人事务部/美国国防部、加拿大心血管学会、欧洲心脏病学会/欧洲动脉粥样硬化学会临床实践指南在一级预防心血管疾病中的他汀类药物使用建议及相关证据水平：人群水平比较。
Circ Cardiovasc Qual Outcomes. 2021 Sep;14(9):e007183. doi: 10.1161/CIRCOUTCOMES.120.007183. Epub 2021 Sep 21.
4
Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.高血压患者的亚临床肾损伤：打开一扇观察心血管系统的肾脏之窗。聚焦微量白蛋白尿。
Adv Exp Med Biol. 2017;956:279-306. doi: 10.1007/5584_2016_85.
5
[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines].[西班牙心血管疾病预防跨学科委员会及西班牙心脏病学会关于血脂异常管理的立场声明。欧洲和美国指南的差异]
Hipertens Riesgo Vasc. 2015 Apr-Jun;32(2):83-91. doi: 10.1016/j.hipert.2014.09.002. Epub 2014 Nov 14.
6
Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.西班牙心血管疾病预防跨学科委员会及西班牙心脏病学会关于血脂异常管理的立场声明。欧洲和美国指南之间的差异。
Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):913-9. doi: 10.1016/j.rec.2014.05.008. Epub 2014 Aug 3.
7
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.在心血管疾病高危人群中，初级预防工作开展得很差：来自欧洲心脏病学会 EURObservational Research Programme EUROASPIRE V 调查的 16 个欧洲国家的报告。
Eur J Prev Cardiol. 2021 May 8;28(4):370-379. doi: 10.1177/2047487320908698. Epub 2020 Mar 20.
8
Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of Hypertension/European Society of Cardiology hypertension guidelines.新的美国或欧洲高血压学会/欧洲心脏病学会高血压指南实施的治疗资格及经济效应
J Hypertens. 2015 Apr;33(4):868-73. doi: 10.1097/HJH.0000000000000466.
9
Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD).社论：2021 年欧洲心脏病学会（ESC）关于动脉粥样硬化性心血管疾病（ASCVD）真实世界预防的指南。
Med Sci Monit. 2021 Oct 25;27:e935172. doi: 10.12659/MSM.935172.
10
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲临床实践心血管疾病预防指南：欧洲心脏病学会和其他学会关于临床实践心血管疾病预防的第六联合工作组（由10个学会的代表和特邀专家组成），由欧洲心血管预防与康复协会（EACPR）特别贡献制定。
Atherosclerosis. 2016 Sep;252:207-274. doi: 10.1016/j.atherosclerosis.2016.05.037.

引用本文的文献

1
The association between the extracellular water-to-total body water ratio and albuminuria in Chinese type 2 diabetes mellitus patients.中国2型糖尿病患者细胞外水与总体水比例和蛋白尿之间的关联。
PeerJ. 2025 Jul 31;13:e19780. doi: 10.7717/peerj.19780. eCollection 2025.
2
Exploring the Interplay Between Kidney Dysfunction and Cardiovascular Disease.探索肾功能不全与心血管疾病之间的相互作用。
Med Sci (Basel). 2025 Jun 18;13(2):80. doi: 10.3390/medsci13020080.
3
International Nephrology Masterclass in Chronic Kidney Disease: Rationale, Summary, and Future Perspectives.国际慢性肾脏病肾病学大师班：基本原理、总结与未来展望。
Life (Basel). 2024 Dec 17;14(12):1668. doi: 10.3390/life14121668.
4
Patterns of kidney function and risk assessment in a nationwide laboratory database: the Brazilian CHECK-CKD study.全国性实验室数据库中肾功能和风险评估模式：巴西 CHECK-CKD 研究。
BMC Nephrol. 2024 Jun 4;25(1):191. doi: 10.1186/s12882-024-03588-w.
5
Pathophysiological concepts and screening of cardiovascular disease in dialysis patients.透析患者心血管疾病的病理生理概念与筛查
Front Nephrol. 2023 Sep 29;3:1198560. doi: 10.3389/fneph.2023.1198560. eCollection 2023.
6
A Cross-Sectional Study on the Prevalence and Risk Stratification of Chronic Kidney Disease in Cardiological Patients in São Paulo, Brazil.巴西圣保罗心脏病患者慢性肾脏病患病率及风险分层的横断面研究
Diagnostics (Basel). 2023 Mar 16;13(6):1146. doi: 10.3390/diagnostics13061146.

本文引用的文献

1
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
2
Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain.西班牙慢性肾脏病患者的流行病学、临床特征、治疗及两年并发症风险
Nefrologia (Engl Ed). 2021 Jun 18. doi: 10.1016/j.nefro.2021.03.006.
3
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
4
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家慢性肾脏病负担，1990-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13.
5
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
6
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
7
Chronic Kidney Disease.慢性肾脏病。
Lancet. 2017 Mar 25;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5. Epub 2016 Nov 23.
8
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.血管紧张素受体拮抗剂厄贝沙坦对2型糖尿病肾病患者的肾脏保护作用。
N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303.
9
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.血管紧张素转换酶抑制剂在非糖尿病性肾病伴非肾病性蛋白尿中的肾脏保护特性。
Lancet. 1999 Jul 31;354(9176):359-64. doi: 10.1016/S0140-6736(98)10363-X.